, Volume 85, Issue 2, pp 134-135
Date: 15 Nov 2005

Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

Antiphospholipid antibody syndrome (APS) is characterized by arterial and venous thrombosis, recurrent fetal loss, and by thrombocytopenia which is presumably autoimmune-mediated. Thrombocytopenia is reported in about 20 to 40% of patients with APS and is usually mild. Although there is direct evidence that antiphospholipid antibodies may bind platelet membranes and cause platelet destruction, the relation between antiphospholipid antibodies and thrombocytopenia is still unclear.

We report a 32-year-old man who initially was diagnosed to have primary APS in June 2004. He presented with deep venous thrombosis, pulmonary embolism, and thrombocytopenia with platelet counts between 29×109/l and 34×109/l. The patient had a prior history of recurrent thromboembolisms and had been on warfarin therapy from 1992 to 2002. His platelet count had been within normal limits and was last documented in 2004. Warfarin was discontinued for unknown reason, and there was no specific treatment a